Corporate / CVC · 1 deal
Every published round Cephalon, Inc. took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Chemgenex | Venture debt | Oct 2010 | $15m | Lead | GBS Ventures (29 Mar 2011), GBS Ventures (22 Oct 2010) |
Companies Cephalon, Inc. has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Chemgenex | Oct 2010, Venture debt | 1 | 1 |
Fund closes reported for Cephalon, Inc., as distinct from the investments it has made.
Companies Cephalon, Inc. has backed that another company then bought. An exit for the holding, not a deal Cephalon, Inc. did.
Stories naming Cephalon, Inc.. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
ChemGenex has signed a convertible note deal giving Cephalon up to A$15 million in notes, plus options over 19.9 percent of shares held by Stragen and Merck; major shareholders back the issue.
Also GBS Ventures
GBS Ventures' letter to Arana Therapeutics shareholders covers Cephalon's proposed cash takeover, an attached dividend, the board's recommendation to accept, and Cephalon's pre-bid purchase of a 19.8% stake.
Cephalon has announced plans to buy out Arana Therapeutics shareholders at $1.40 a share, potentially $1.45, valuing the ASX-listed target around $318 million; its independent directors back the bid unless a better one emerges.